Q2 FY2026 EarningsQ2 FY26 results beat consensus across the board, though the company remains in a pre-commercial, heavy-loss phase. Revenue of $0.17M slightly exceeded the $0.13M expected, while the net loss of $6.28M was significantly narrower than the anticipated $8.78M. EPS (GAAP) of -$1.46 notably beat the consensus estimate of -$3.00, primarily driven by disciplined OpEx management and a substantial increase in weighted average shares following recent equity financing.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Co-Diagnostics(CODX) the Revenue is 166.13 K (+1.98%), Beat estimate;the EBIT is -6.201 M (+23.05%), Beat estimate;the EPS is -1.46 (+78.84%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.00B1.98%
0.00B18.36%
+0.00B20.34%
EBITExceed expectations
-0.01B23.05%
-0.01B9.01%
+0.00B32.06%
EPSExceed expectations
-1.4678.84%
-356.52%
+1.540022.32%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf